Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03395080 · OUTCOME

Progression-free Survival (PFS) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).

A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma · Source last updated 2025-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
Baseline to study completion (maximum 7.1 months)

What was measured

Progression-free survival (PFS) is defined as time from first dose of study drug to first documentation of PD (per RECIST 1.1) or death due to any cause.

Analysis population: Full Analysis Set (FAS), all subjects who received any amount of DKN-01.

Groups in this outcome

DKN-01 Monotherapy in Recurrent EEC

300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.

DKN-01 + Paclitaxel in Recurrent EEC

300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.

DKN-01 Monotherapy in Recurrent EOC

300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.

DKN-01 + Paclitaxel in Recurrent EOC

300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.

DKN-01 300mg Monotherapy in Carcinosarcoma

300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.

DKN-01 600mg Monotherapy in Carcinosarcoma

600mg DKN-01 onotherapy in carcinosarcoma. DKN-01 administered by IV infusion.

DKN-01 300mg + Paclitaxel in Carcinosarcoma

300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.

DKN-01 600mg + Paclitaxel in Carcinosarcoma

600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
DKN-01 Monotherapy in Recurrent EEC29
DKN-01 + Paclitaxel in Recurrent EEC24
DKN-01 Monotherapy in Recurrent EOC14
DKN-01 + Paclitaxel in Recurrent EOC19
DKN-01 300mg Monotherapy in Carcinosarcoma1
DKN-01 600mg Monotherapy in Carcinosarcoma8
DKN-01 300mg + Paclitaxel in Carcinosarcoma4
DKN-01 600mg + Paclitaxel in Carcinosarcoma10

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
DKN-01 Monotherapy in Recurrent EEC1.8Not reported1.75.5Not reported
DKN-01 + Paclitaxel in Recurrent EEC3.8Not reported1.85.4Not reported
DKN-01 Monotherapy in Recurrent EOC2.1Not reported1.63.5Not reported
DKN-01 + Paclitaxel in Recurrent EOC3.6Not reported1.87.1Not reported
DKN-01 300mg Monotherapy in Carcinosarcoma11.6Not reportedNANANA=not estimable. Data are not estimable due to insufficient number of participants with events.
DKN-01 600mg Monotherapy in Carcinosarcoma1.6Not reported0.57.9Not reported
DKN-01 300mg + Paclitaxel in Carcinosarcoma2.0Not reported1.85.5Not reported
DKN-01 600mg + Paclitaxel in Carcinosarcoma1.9Not reported0.94.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.7
        upper Limit
        5.5
        value
        1.8
      2. group Id
        OG001
        lower Limit
        1.8
        upper Limit
        5.4
        value
        3.8
      3. group Id
        OG002
        lower Limit
        1.6
        upper Limit
        3.5
        value
        2.1
      4. group Id
        OG003
        lower Limit
        1.8
        upper Limit
        7.1
        value
        3.6
      5. comment
        NA=not estimable. Data are not estimable due to insufficient number of participants with events.
        group Id
        OG004
        lower Limit
        NA
        upper Limit
        NA
        value
        11.6
      6. group Id
        OG005
        lower Limit
        0.5
        upper Limit
        7.9
        value
        1.6
      7. group Id
        OG006
        lower Limit
        1.8
        upper Limit
        5.5
        value
        2.0
      8. group Id
        OG007
        lower Limit
        0.9
        upper Limit
        4.0
        value
        1.9
denoms
  1. counts
    1. group Id
      OG000
      value
      29
    2. group Id
      OG001
      value
      24
    3. group Id
      OG002
      value
      14
    4. group Id
      OG003
      value
      19
    5. group Id
      OG004
      value
      1
    6. group Id
      OG005
      value
      8
    7. group Id
      OG006
      value
      4
    8. group Id
      OG007
      value
      10
    units
    Participants
description
Progression-free survival (PFS) is defined as time from first dose of study drug to first documentation of PD (per RECIST 1.1) or death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.
    id
    OG000
    title
    DKN-01 Monotherapy in Recurrent EEC
  2. description
    300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG001
    title
    DKN-01 + Paclitaxel in Recurrent EEC
  3. description
    300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.
    id
    OG002
    title
    DKN-01 Monotherapy in Recurrent EOC
  4. description
    300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG003
    title
    DKN-01 + Paclitaxel in Recurrent EOC
  5. description
    300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.
    id
    OG004
    title
    DKN-01 300mg Monotherapy in Carcinosarcoma
  6. description
    600mg DKN-01 onotherapy in carcinosarcoma. DKN-01 administered by IV infusion.
    id
    OG005
    title
    DKN-01 600mg Monotherapy in Carcinosarcoma
  7. description
    300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG006
    title
    DKN-01 300mg + Paclitaxel in Carcinosarcoma
  8. description
    600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.
    id
    OG007
    title
    DKN-01 600mg + Paclitaxel in Carcinosarcoma
param Type
MEDIAN
population Description
Full Analysis Set (FAS), all subjects who received any amount of DKN-01.
reporting Status
POSTED
time Frame
Baseline to study completion (maximum 7.1 months)
title
Progression-free Survival (PFS) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice